Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.840
-0.005 (-0.56%)
At close: Jan 21, 2025, 4:00 PM
0.852
+0.012 (1.39%)
After-hours: Jan 21, 2025, 7:03 PM EST
Jaguar Health Revenue
Jaguar Health had revenue of $3.11M in the quarter ending September 30, 2024, with 10.49% growth. This brings the company's revenue in the last twelve months to $10.48M, down -2.25% year-over-year. In the year 2023, Jaguar Health had annual revenue of $9.76M, down -18.36%.
Revenue (ttm)
$10.48M
Revenue Growth
-2.25%
P/S Ratio
0.37
Revenue / Employee
$213,878
Employees
49
Market Cap
9.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 9.76M | -2.20M | -18.36% |
| Dec 31, 2022 | 11.96M | 7.62M | 175.80% |
| Dec 31, 2021 | 4.34M | -5.05M | -53.81% |
| Dec 31, 2020 | 9.39M | 3.61M | 62.51% |
| Dec 31, 2019 | 5.78M | 1.36M | 30.77% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2007 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
JAGX News
- 11 days ago - Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Accesswire
- 13 days ago - Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase - Accesswire
- 14 days ago - Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum - Accesswire
- 4 weeks ago - Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications - Accesswire
- 4 weeks ago - Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder - Accesswire
- 5 weeks ago - FDA Approves Orphan-Drug Designation for Jaguar Health's Crofelemer for Treatment of Diarrhea in Cholera - Accesswire
- 5 weeks ago - Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer - Accesswire
- 5 weeks ago - Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS) - Accesswire